Lindsay Androski
President and CEO, Director · Arbutus Biopharma Corp
Individual
- 2024
- Oct 7, 2026
- 4
Other insiders active in the same sector
No other insider has filed at Lindsay Androski's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- R01 Fund LP - $45.65M in SDEV purchases and sales in the last 12 months
- Michael John Kazley - $45.65M in SDEV purchases and sales in the last 12 months
- Stephen Hoge - $45.45M in MRNA purchases and sales in the last 12 months
- Neil Kumar - $45.20M in BBIO purchases and sales in the last 12 months
- James C. Foster - $43.26M in CRL purchases and sales in the last 12 months
- Framework Ventures IV L.P. - $42.62M in SDEV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Lindsay Androski?
Lindsay Androski is a corporate insider, tracked as President and CEO, Director of Arbutus Biopharma Corp (ABUS). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Lindsay Androski submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
